Last updated: July 28, 2026
MAXZIDE-25 (triamterene 37.5 mg / hydrochlorothiazide 25 mg) clinical trials update, market analysis, and exclusivity-and-generic-entry projection
MAXZIDE-25 is an established, fixed-dose combination diuretic (triamterene + hydrochlorothiazide) with a long commercial history. Market projections and a forward-looking generic-entry timeline depend on (i) the active NDA/ANDA landscape for the specific strength “MAXZIDE-25” and (ii) the date when the relevant brand and any downstream Orange Book listed patents expire for the US market. No complete, authoritative dataset (FDA Orange Book listings, patent numbers/expiration dates tied to MAXZIDE-25, ANDA approvals, or current clinical trial registries mapped to this exact trade strength) is available in the provided materials.
Per the operating constraints, no partial or speculative projection is provided.
What clinical trials exist for MAXZIDE-25 (triamterene hydrochlorothiazide 37.5/25)?
Answer: No trial registry update can be produced for the specific product strength “MAXZIDE-25” using only the information provided.
Which trial types would normally be relevant for this combination diuretic?
- Pharmacokinetic (PK) or bioequivalence studies comparing fixed-dose combination versus reference products
- Safety/tolerability studies in populations with hypertension or edema
- Trials assessing electrolyte changes (potassium, sodium, chloride), renal parameters, and diuretic response
- Real-world evidence studies (health system databases) tied to the branded strength
Clinical trials update required for a complete answer is not available.
How big is the MAXZIDE-25 market and who buys it?
Answer: Market sizing, buyer concentration, and channel mix for “MAXZIDE-25” cannot be quantified without the specific brand-level market series and attribution rules (brand vs NDC-level vs molecule-level reporting) for the exact strength.
What data is typically needed for a defensible market analysis
- NDC-level sales (brand MAXZIDE-25) or FDA MIDAS by product identifier
- Prescriber specialty and geographic distribution
- Payer mix (Medicare Part D, Medicaid, commercial)
- Generic penetration by molecule strength and product form
- Switching patterns across diuretic classes (thiazide-like diuretics, potassium-sparing combinations)
A complete dataset is not available.
When does MAXZIDE-25 lose exclusivity in the US?
Answer: An exclusivity and patent-expiration timeline cannot be produced without Orange Book patent and exclusivity records mapped to the MAXZIDE-25 formulation/strength.
What exclusivity events typically govern older combination products
- Patent expiry for listed formulation, method-of-use, or manufacturing process patents
- Orange Book “Orange Book listed” expiration vs “regulatory exclusivity”
- Generic launch risk at different carve-outs (method-of-use vs formulation)
No patent/exclusivity records are provided.
What patents protect MAXZIDE-25 and how strong is the estate?
Answer: A patent-coverage and strength assessment cannot be generated without identifying the Orange Book patent numbers and assignees for MAXZIDE-25 and relevant family members.
What would be assessed if records were available
- Composition-of-matter vs formulation vs process vs method-of-use coverage
- Litigation history (CAs, Hatch-Waxman suits, settlements)
- Claim breadth and typical invalidity risks (obviousness, enablement, written description)
- Geographic coverage (US filings only vs international family use)
No patent dataset is available in the prompt.
What generic entry risks exist for MAXZIDE-25 (Paragraph IV, ANDA timing)?
Answer: Paragraph IV risk and ANDA timing cannot be forecast without:
- active ANDAs for the strength
- any pending Paragraph IV litigation tied to the Orange Book patents
- relevant court calendars and settlement agreements
No litigation and ANDA status is provided.
What is the Orange Book status of MAXZIDE-25?
Answer: The Orange Book status (listed patents, expiration dates, exclusivity codes, and NDA/brand references) cannot be reported because the required FDA Orange Book record for MAXZIDE-25 is not supplied.
Which companies manufacture and market MAXZIDE-25, and how does the competitive landscape look?
Answer: Company and competitive landscape cannot be enumerated without NDC manufacturer mapping and current brand vs generic product roster for 37.5/25.
How does MAXZIDE-25 compare with hydrochlorothiazide alone or other triamterene combinations?
Answer: Comparative analysis cannot be produced without sales/reimbursement context and product roster for alternatives (e.g., other triamterene-HCTZ strengths and HCTZ-only regimens) in the US market.
What patent litigation affects diuretic combinations like MAXZIDE-25?
Answer: Litigation impacts cannot be identified without case names, docket numbers, and links to the specific Orange Book patents for the MAXZIDE-25 formulation.
How should MAXZIDE-25 market projections be modeled (scenario framework)?
Answer: A projection model cannot be completed without actual baseline sales, current generic penetration, and the exact exclusivity/patent termination dates that drive step-function declines.
Inputs a projection normally requires
- Current annual sales baseline (brand)
- Elasticity of switching post-patent expiry
- Generic launch timing distribution and expected entrants
- Discounting and payer reimbursement changes
- Net price erosion and wholesaler inventory effects
These inputs are not available.
Key Takeaways
- A product-specific clinical trials update, market sizing, and exclusivity-and-generic-entry projection for MAXZIDE-25 cannot be completed from the provided information.
- Producing a defensible analysis requires mapping MAXZIDE-25 to the correct FDA identifiers (NDA and NDCs), Orange Book patent listings, ANDA approvals, and any active litigation records for the exact strength.
FAQs
- What is the FDA regulatory status of MAXZIDE-25 (NDA/ANDA reference and labeling history)?
- Are there any current bioequivalence studies specifically for triamterene 37.5 mg / hydrochlorothiazide 25 mg fixed-dose combinations?
- Which Orange Book patents list protection for MAXZIDE-25 and what are their expiration dates?
- What generic products (by NDC) currently compete with MAXZIDE-25 in the US?
- How do payer formularies typically position triamterene-HCTZ combinations versus thiazide diuretics alone?
References
No sources were cited because the necessary MAXZIDE-25 specific FDA and trial/patent datasets are not present in the provided prompt.
